[시장보고서]응고인자 결핍증 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 형태별, 디바이스별, 솔루션별(-2035년)

응고인자 결핍증 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 형태별, 디바이스별, 솔루션별(-2035년)

Coagulation Factor Deficiency Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Form, Device, Solutions

상품코드 : 1954240

리서치사 : Global Insight Services

발행일 : 2026년 02월

페이지 정보 : 영문 372 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,750

￦ 7,170,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.

US $ 5,750

￦ 8,679,000

PDF & Excel (Site License)

PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.

US $ 6,750

￦ 10,189,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

응고인자 결핍증 시장은 2024년 55억 달러에서 2034년까지 95억 달러로 확대될 전망이며, CAGR 약 6.6%를 나타낼 것으로 예측됩니다. 응고인자 결핍증 시장은 혈우병 및 폰 빌레브랜드병과 같은 출혈성 질환의 관리에 필수적인 혈액 응고 인자의 결핍에 대처하는 제품 및 치료법을 대상으로 합니다. 이 시장은 재조합 및 혈장 유래의 응고 인자 농축 제제, 유전자 치료 및 새로운 치료 접근법을 포함합니다. 인지도 향상, 의료 기술 진보 및 출혈성 질환의 발생률 증가는 시장 성장을 가속하고 맞춤형 의료 및 환자 결과 개선에 중점을 둡니다.

응고인자 결핍증 시장은 치료법의 진보와 출혈성 질환에 대한 인식 향상을 배경으로 대폭적인 성장이 전망되고 있습니다. 시장을 견인하는 것은 재조합 응고인자 농축물 부문이며, 혈장 유래 제품에 비해 안전성 및 효능성이 향상하고 있습니다. 이 중 VIII인자 농축물이 가장 높은 성장률을 보이며 A형 혈우병 환자의 요구에 대응하고 있습니다. 인자 IX 농축 제제는 이어서 혈우병 B 환자층에 제공됩니다. 예방적 치료 부문도 견조한 실적을 보이며 출혈 에피소드의 감소와 환자의 삶의 질 향상을 위한 예방 의료로의 전환을 반영합니다. 맞춤형 의료에 대한 수요가 높아지는 가운데, 유전자 치료가 유망한 새로운 영역으로서 대두하고 있습니다. 이 혁신 기술은 응고인자 결핍에 대한 장기적인 해결책을 제공하고 치료 패러다임을 변화시킬 잠재력을 가지고 있습니다. 또한, 투여 빈도를 줄이고 환자의 치료 지속률을 높이는 것을 목적으로 하는 반감기 연장 제품의 개발도 기세를 늘리고 있습니다. 이러한 추세는 시장의 역동적인 진화와 이해관계자들에게 수익성 있는 기회를 돋보이게 합니다.

시장 세분화
유형별	혈우병 A, 혈우병 B, 폰 빌레브랜드병, 인자 II 결핍, 인자 V 결핍, 인자 VII 결핍, 인자 X 결핍, 인자 XI 결핍, 인자 XIII 결핍
제품별	혈장 유래 응고인자, 재조합 응고인자
서비스별	진단 서비스, 상담 서비스, 치료 서비스
기술별	유전자 치료, 단백질 보충 요법
용도별	예방, 온디맨드 치료, 수술
최종 사용자	병원, 전문 클리닉, 재택치료 환경
형태별	주사제, 경구제
디바이스별	주입 장치, 모니터링 장비
솔루션별	환자 관리, 재고 관리

응고인자 결핍증 시장은 시장 점유율과 가격 전략에 큰 변화를 보이는 역동적인 상황에 있습니다. 주요 기업은 미충족 요구에 대응하고 환자의 치료 성과를 향상시키는 것을 목표로 혁신적인 제품을 적극적으로 도입하고 있습니다. 이러한 전략적 도입은 경쟁적 위치를 재구성하고 치료 옵션을 확대하고 있습니다. 가격 설정은 경쟁이 치열하고 지역 시장 수요와 상환 정책의 영향을 받고 있으며, 이들은 환자에게 접근성 및 저렴한 가격을 결정하는 데 매우 중요합니다. 경쟁 벤치마킹은 확립된 제약 대기업과 신흥 생명 공학 기업이 시장 지배를 다투는 동안 양자가 확고한 존재감을 보여준다는 것이 분명합니다. 특히 북미 및 유럽에서의 규제의 영향은 승인 프로세스 및 규정 준수 기준을 규정하고 시장 역학을 형성하는 데 매우 중요합니다. 본 시장은 치료 효과 및 안전성 향상을 추진하는 연구개발 투자에 대한 강한 주력이 특징입니다. 규제 상황이 변화하는 가운데, 각사는 엄격한 가이드라인에 대응하기 위해 전략적으로 제품 포트폴리오를 조정하여 지속적인 성장과 시장 침투를 도모하고 있습니다. 첨단 기술과 개인화된 의료 접근법의 통합은 추가 시장 확대를 촉진할 것으로 예측됩니다.

주요 동향 및 촉진요인 :

응고인자 결핍증 시장은 몇 가지 새로운 동향과 영향력있는 촉진요인에 의해 현저한 확장을 경험하고 있습니다. 주요 동향 중 하나는 세계 출혈성 질환의 유병률 증가이며 고급 치료 솔루션이 필요합니다. 이 급증은 진단 능력의 향상과 인식의 고조에 의한 조기 발견 및 조기 개입이 요인입니다. 또한 재조합 DNA 기술의 현저한 진보가 혁신적이고 효과적인 치료법의 개발로 이어지고 있습니다. 또 다른 중요한 동향은 맞춤형 의료에 대한 지향 증가이며 환자의 치료 성과를 향상시키는 맞춤형 치료 계획을 가능하게 하고 있습니다. 치료를 자택에서 실시하는 재택 치료 환경의 보급도 기세를 늘리고 있어 편리성의 향상과 의료비 삭감을 실현하고 있습니다. 이 시장 성장 촉진요인으로는 응고장애에 걸리기 쉬운 고령화가 진행되는 세계인구와 헬스케어 인프라에 대한 투자 증가를 들 수 있습니다. 또한 희귀질환의 치료에 대한 액세스 개선을 목표로 정부의 이니셔티브가 시장 성장을 가속하고 있습니다. 헬스케어 시스템이 발전 도상에 있는 신흥 경제국에는 시장 진입의 호기가 많이 존재합니다. 연구개발 및 전략적 제휴에 주력하는 기업은 이러한 기회를 최대한 활용하고 응고인자 결핍증 시장에서 지속적인 성장과 혁신을 실현하는 데 유리한 입장에 있습니다.

시장 규모 및 예측 : 유형별
- 혈우병 A
- 혈우병 B
- 폰 빌레 브랜드 병
- 인자 II 결핍증
- 인자 V 결핍증
- 인자 VII 결핍증
- 인자 X 결핍증
- 인자 XI 결핍증
- 인자 XIII 결핍증
시장 규모 및 예측 : 제품별
- 혈장 유래 응고인자
- 재조합 응고인자
시장 규모 및 예측 : 서비스별
- 진단 서비스
- 컨설팅 서비스
- 치료 서비스
시장 규모 및 예측 : 기술별
- 유전자 치료
- 단백질 보충 요법
시장 규모 및 예측 : 용도별
- 예방 요법
- 온디맨드 치료
- 수술 수술
시장 규모 및 예측 : 최종 사용자별
- 병원
- 전문 클리닉
- 재택 치료 환경
시장 규모 및 예측 : 형태별
- 주사제
- 경구
시장 규모 및 예측 : 디바이스별
- 주입 장치
- 모니터링 장치
시장 규모 및 예측 : 솔루션별
- 환자 관리
- 재고 관리

제5장 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
라틴아메리카
- 브라질
- 아르헨티나
- 기타 라틴아메리카
아시아태평양
- 중국
- 인도
- 한국
- 일본
- 호주
- 대만
- 기타 아시아태평양
유럽
- 독일
- 프랑스
- 영국
- 스페인
- 이탈리아
- 기타 유럽
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카
- 서브 사하라 아프리카
- 기타 중동 및 아프리카

제6장 시장 전략

수요 및 공급의 갭 분석
무역 및 물류 상의 제약
가격, 비용 및 마진의 동향
시장 침투
소비자 분석
규제 개요

제7장 경쟁 정보

시장 포지셔닝
시장 점유율
경쟁 벤치마킹
주요 기업의 전략

제8장 기업 프로파일

Octapharma
CSL Behring
Kedrion Biopharma
Grifols
Sobi
LFB Group
Bio Products Laboratory
Sanquin
Green Cross Corporation
Shanghai RAAS Blood Products
Baxter International
Biotest AG
Hualan Biological Engineering
Shire
Pfizer
Novo Nordisk
Bayer Healthcare
Takeda Pharmaceutical
Ferring Pharmaceuticals
Sanofi Genzyme

제9장 당사에 대해서

AJY

영문 목차

영문목차

Coagulation Factor Deficiency Market is anticipated to expand from $5.5 billion in 2024 to $9.5 billion by 2034, growing at a CAGR of approximately 6.6%. The Coagulation Factor Deficiency Market encompasses products and therapies addressing deficiencies in blood clotting factors, critical for managing bleeding disorders like hemophilia and von Willebrand disease. This market includes recombinant and plasma-derived factor concentrates, gene therapies, and novel treatment approaches. Increasing awareness, advancements in medical technology, and rising incidence of bleeding disorders propel market growth, with a focus on personalized medicine and improved patient outcomes.

The Coagulation Factor Deficiency Market is poised for substantial growth, driven by advancements in treatment options and increasing awareness of bleeding disorders. The recombinant coagulation factor concentrates segment leads the market, offering enhanced safety and efficacy over plasma-derived products. Among these, Factor VIII concentrates are the top-performing sub-segment, addressing the needs of Hemophilia A patients. Factor IX concentrates follow closely, serving the Hemophilia B population. The prophylaxis treatment segment also exhibits strong performance, reflecting a shift towards preventive care to reduce bleeding episodes and improve patient quality of life. Demand for personalized medicine is rising, with gene therapy emerging as a promising frontier. This innovation aims to offer long-term solutions for coagulation deficiencies, potentially transforming treatment paradigms. Furthermore, the development of extended half-life products is gaining momentum, aiming to reduce the frequency of administration and enhance patient adherence. These trends underscore the market's dynamic evolution and lucrative opportunities for stakeholders.

Market Segmentation
Type	Hemophilia A, Hemophilia B, Von Willebrand Disease, Factor II Deficiency, Factor V Deficiency, Factor VII Deficiency, Factor X Deficiency, Factor XI Deficiency, Factor XIII Deficiency
Product	Plasma-derived Coagulation Factors, Recombinant Coagulation Factors
Services	Diagnostic Services, Consultation Services, Therapeutic Services
Technology	Gene Therapy, Protein Replacement Therapy
Application	Prophylaxis, On-demand Treatment, Surgery
End User	Hospitals, Specialty Clinics, Homecare Settings
Form	Injectables, Oral
Device	Infusion Devices, Monitoring Devices
Solutions	Patient Management, Inventory Management

The Coagulation Factor Deficiency Market is witnessing a dynamic landscape with significant shifts in market share and pricing strategies. Key players are actively launching innovative products, aiming to address unmet medical needs and improve patient outcomes. These strategic introductions are reshaping competitive positioning and enhancing therapeutic options. Pricing remains competitive, influenced by regional market demands and reimbursement policies, which are pivotal in determining accessibility and affordability for patients. Competition benchmarking reveals a robust presence of established pharmaceutical giants alongside emerging biotechs, each vying for market dominance. Regulatory influences, particularly in North America and Europe, are critical in shaping market dynamics, dictating approval pathways and compliance standards. The market is characterized by a strong focus on R&D investments, driving advancements in treatment efficacy and safety. As regulatory landscapes evolve, companies are strategically aligning their portfolios to meet stringent guidelines, ensuring sustained growth and market penetration. The integration of advanced technologies and personalized medicine approaches is anticipated to further propel market expansion.

Geographical Overview:

The Coagulation Factor Deficiency Market is witnessing varied growth trajectories across regions. North America remains at the forefront, driven by advanced healthcare infrastructure and increased awareness of bleeding disorders. The presence of leading pharmaceutical companies further consolidates its position. Europe follows, with significant investments in research and development for innovative treatments, alongside favorable reimbursement policies supporting market growth. In Asia Pacific, the market is expanding rapidly due to rising healthcare expenditure and increased diagnosis rates of coagulation disorders. Emerging economies like China and India are pivotal, with growing investments in healthcare and expanding patient populations. Latin America is also gaining traction, with Brazil and Mexico showing promising growth due to improved healthcare access and government initiatives. The Middle East & Africa are nascent yet emerging markets, with increasing recognition of coagulation disorders and gradual improvements in healthcare infrastructure. These regions present untapped opportunities for market expansion and innovation in treatment modalities.

The Coagulation Factor Deficiency Market is intricately influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, strategies are increasingly geared towards enhancing domestic production capabilities to mitigate tariff-induced costs and geopolitical uncertainties. China is intensifying efforts to bolster its self-sufficiency in biopharmaceuticals amidst export restrictions, whereas Taiwan is leveraging its advanced biotech sector while navigating geopolitical tensions. The parent market is experiencing robust growth globally, driven by rising healthcare demands and technological advancements. By 2035, the market is poised for significant expansion, contingent upon strategic alliances and resilient supply chains. Furthermore, Middle East conflicts could indirectly affect this market by influencing global energy prices, thereby impacting manufacturing and distribution costs across the sector.

Key Trends and Drivers:

The Coagulation Factor Deficiency Market is experiencing notable expansion driven by several emerging trends and influential drivers. A primary trend is the increased prevalence of bleeding disorders worldwide, necessitating advanced treatment solutions. This surge is attributed to enhanced diagnostic capabilities and heightened awareness, prompting early detection and intervention. Additionally, the market is witnessing substantial advancements in recombinant DNA technology, leading to the development of innovative and effective therapies. Another significant trend is the growing inclination towards personalized medicine, allowing for tailored treatment regimens that enhance patient outcomes. The rise of homecare settings for administering treatments is also gaining momentum, offering convenience and reducing healthcare costs. Drivers of this market include the aging global population, which is more susceptible to coagulation disorders, and the increasing investment in healthcare infrastructure. Moreover, government initiatives aimed at improving access to treatment for rare diseases are fostering market growth. Opportunities abound in emerging economies where healthcare systems are evolving, presenting a fertile ground for market penetration. Companies focusing on research and development, along with strategic partnerships, are well-positioned to capitalize on these opportunities, ensuring sustained growth and innovation in the Coagulation Factor Deficiency Market.

Research Scope:

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Services
2.4 Key Market Highlights by Technology
2.5 Key Market Highlights by Application
2.6 Key Market Highlights by End User
2.7 Key Market Highlights by Form
2.8 Key Market Highlights by Device
2.9 Key Market Highlights by Solutions

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Hemophilia A
- 4.1.2 Hemophilia B
- 4.1.3 Von Willebrand Disease
- 4.1.4 Factor II Deficiency
- 4.1.5 Factor V Deficiency
- 4.1.6 Factor VII Deficiency
- 4.1.7 Factor X Deficiency
- 4.1.8 Factor XI Deficiency
- 4.1.9 Factor XIII Deficiency
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Plasma-derived Coagulation Factors
- 4.2.2 Recombinant Coagulation Factors
4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Diagnostic Services
- 4.3.2 Consultation Services
- 4.3.3 Therapeutic Services
4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 Gene Therapy
- 4.4.2 Protein Replacement Therapy
4.5 Market Size & Forecast by Application (2020-2035)
- 4.5.1 Prophylaxis
- 4.5.2 On-demand Treatment
- 4.5.3 Surgery
4.6 Market Size & Forecast by End User (2020-2035)
- 4.6.1 Hospitals
- 4.6.2 Specialty Clinics
- 4.6.3 Homecare Settings
4.7 Market Size & Forecast by Form (2020-2035)
- 4.7.1 Injectables
- 4.7.2 Oral
4.8 Market Size & Forecast by Device (2020-2035)
- 4.8.1 Infusion Devices
- 4.8.2 Monitoring Devices
4.9 Market Size & Forecast by Solutions (2020-2035)
- 4.9.1 Patient Management
- 4.9.2 Inventory Management

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Services
  - 5.2.1.4 Technology
  - 5.2.1.5 Application
  - 5.2.1.6 End User
  - 5.2.1.7 Form
  - 5.2.1.8 Device
  - 5.2.1.9 Solutions
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Services
  - 5.2.2.4 Technology
  - 5.2.2.5 Application
  - 5.2.2.6 End User
  - 5.2.2.7 Form
  - 5.2.2.8 Device
  - 5.2.2.9 Solutions
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Services
  - 5.2.3.4 Technology
  - 5.2.3.5 Application
  - 5.2.3.6 End User
  - 5.2.3.7 Form
  - 5.2.3.8 Device
  - 5.2.3.9 Solutions
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Services
  - 5.3.1.4 Technology
  - 5.3.1.5 Application
  - 5.3.1.6 End User
  - 5.3.1.7 Form
  - 5.3.1.8 Device
  - 5.3.1.9 Solutions
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Services
  - 5.3.2.4 Technology
  - 5.3.2.5 Application
  - 5.3.2.6 End User
  - 5.3.2.7 Form
  - 5.3.2.8 Device
  - 5.3.2.9 Solutions
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Services
  - 5.3.3.4 Technology
  - 5.3.3.5 Application
  - 5.3.3.6 End User
  - 5.3.3.7 Form
  - 5.3.3.8 Device
  - 5.3.3.9 Solutions
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Services
  - 5.4.1.4 Technology
  - 5.4.1.5 Application
  - 5.4.1.6 End User
  - 5.4.1.7 Form
  - 5.4.1.8 Device
  - 5.4.1.9 Solutions
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Services
  - 5.4.2.4 Technology
  - 5.4.2.5 Application
  - 5.4.2.6 End User
  - 5.4.2.7 Form
  - 5.4.2.8 Device
  - 5.4.2.9 Solutions
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Services
  - 5.4.3.4 Technology
  - 5.4.3.5 Application
  - 5.4.3.6 End User
  - 5.4.3.7 Form
  - 5.4.3.8 Device
  - 5.4.3.9 Solutions
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Services
  - 5.4.4.4 Technology
  - 5.4.4.5 Application
  - 5.4.4.6 End User
  - 5.4.4.7 Form
  - 5.4.4.8 Device
  - 5.4.4.9 Solutions
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Services
  - 5.4.5.4 Technology
  - 5.4.5.5 Application
  - 5.4.5.6 End User
  - 5.4.5.7 Form
  - 5.4.5.8 Device
  - 5.4.5.9 Solutions
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Services
  - 5.4.6.4 Technology
  - 5.4.6.5 Application
  - 5.4.6.6 End User
  - 5.4.6.7 Form
  - 5.4.6.8 Device
  - 5.4.6.9 Solutions
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Services
  - 5.4.7.4 Technology
  - 5.4.7.5 Application
  - 5.4.7.6 End User
  - 5.4.7.7 Form
  - 5.4.7.8 Device
  - 5.4.7.9 Solutions
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Services
  - 5.5.1.4 Technology
  - 5.5.1.5 Application
  - 5.5.1.6 End User
  - 5.5.1.7 Form
  - 5.5.1.8 Device
  - 5.5.1.9 Solutions
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Services
  - 5.5.2.4 Technology
  - 5.5.2.5 Application
  - 5.5.2.6 End User
  - 5.5.2.7 Form
  - 5.5.2.8 Device
  - 5.5.2.9 Solutions
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Services
  - 5.5.3.4 Technology
  - 5.5.3.5 Application
  - 5.5.3.6 End User
  - 5.5.3.7 Form
  - 5.5.3.8 Device
  - 5.5.3.9 Solutions
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Services
  - 5.5.4.4 Technology
  - 5.5.4.5 Application
  - 5.5.4.6 End User
  - 5.5.4.7 Form
  - 5.5.4.8 Device
  - 5.5.4.9 Solutions
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Services
  - 5.5.5.4 Technology
  - 5.5.5.5 Application
  - 5.5.5.6 End User
  - 5.5.5.7 Form
  - 5.5.5.8 Device
  - 5.5.5.9 Solutions
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Services
  - 5.5.6.4 Technology
  - 5.5.6.5 Application
  - 5.5.6.6 End User
  - 5.5.6.7 Form
  - 5.5.6.8 Device
  - 5.5.6.9 Solutions
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Services
  - 5.6.1.4 Technology
  - 5.6.1.5 Application
  - 5.6.1.6 End User
  - 5.6.1.7 Form
  - 5.6.1.8 Device
  - 5.6.1.9 Solutions
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Services
  - 5.6.2.4 Technology
  - 5.6.2.5 Application
  - 5.6.2.6 End User
  - 5.6.2.7 Form
  - 5.6.2.8 Device
  - 5.6.2.9 Solutions
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Services
  - 5.6.3.4 Technology
  - 5.6.3.5 Application
  - 5.6.3.6 End User
  - 5.6.3.7 Form
  - 5.6.3.8 Device
  - 5.6.3.9 Solutions
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Services
  - 5.6.4.4 Technology
  - 5.6.4.5 Application
  - 5.6.4.6 End User
  - 5.6.4.7 Form
  - 5.6.4.8 Device
  - 5.6.4.9 Solutions
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Services
  - 5.6.5.4 Technology
  - 5.6.5.5 Application
  - 5.6.5.6 End User
  - 5.6.5.7 Form
  - 5.6.5.8 Device
  - 5.6.5.9 Solutions

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 Octapharma
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 CSL Behring
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Kedrion Biopharma
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Grifols
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 Sobi
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 LFB Group
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 Bio Products Laboratory
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 Sanquin
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 Green Cross Corporation
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 Shanghai RAAS Blood Products
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 Baxter International
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 Biotest AG
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Hualan Biological Engineering
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Shire
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 Pfizer
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 Novo Nordisk
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 Bayer Healthcare
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Takeda Pharmaceutical
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Ferring Pharmaceuticals
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 Sanofi Genzyme
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis

9 About Us

9.1 About Us
9.2 Research Methodology
9.3 Research Workflow
9.4 Consulting Services
9.5 Our Clients
9.6 Client Testimonials
9.7 Contact Us